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The U3-LTR region of leukemia viruses transactivates cancer-related signaling pathways through the
production of a non-coding RNA transcript although the role of this transcript in virus infection
remains unknown. In this study we demonstrate for the ﬁrst time that an long terminal repeat
(LTR)-speciﬁc small non-coding RNA is produced from a feline leukemia virus (FeLV)-infected feline
cell line. RNA cloning identiﬁed this as a 104 base transcript that originates from the U3-LTR region.
We also demonstrate that in in vitro assays this LTR-RNA transcript activates NFjB signaling. Taken
together, our ﬁndings suggest a possible role for this LTR transcript in FeLV pathogenesis.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Long terminal repeat (LTR) regions of oncogene-deﬁcient leu-
kemia viruses such as murine leukemia virus (MuLV) or feline
leukemia virus (FeLV), play an important role in their pathogen-
esis. Proto-oncogene activation by means of its strong promoter
activity at the site of integration of the provirus is the most well
understood function of the LTR [1–4]. Tissue-tropism, disease-
speciﬁcity and pathogenic potential of leukemia viruses are also
determined by the LTR [5–7]. Transcriptional enhancers present
within the U3 region of the LTRs of MuLVs and FeLVs and selec-
tive expression of transcription factors in different tissues, impart
these functionalities to the LTR. LTRs have also been implicated
in the development of the preleukemic hematopoietic hyperpla-
sia seen in leukemia virus-infected animals. Insertion of unre-
lated sequences such as the enhancer element of polyomavirus
into the U3-LTR of Mo-MuLV has been shown to abrogate such
hyperplasia and reduce the tumorigenic potential of the virus
[8,9].
Several other studies demonstrated that LTR region of Mo-
MuLV and FeLV independently activate AP-1 and NFjB signaling
pathways, which are intimately associated with the cancer devel-
opment [10–14]. It was suggested that induction of these path-
ways could provide an actively growing target cell population for
secondary infection and thereby presumably increases the chance
of insertional activation of proto-oncogenes. A search for the min-
imum sequence necessary for LTR-mediated cellular gene transac-chemical Societies. Published by Etivation demonstrated that the U5 and R regions were not
necessary. In case of Mo-MuLV, the ﬁrst 300 bases of the U3 region
was sufﬁcient for this activity [15]. A more detailed study on FeLV
demonstrated that the length of the fragment could be even smal-
ler [16]. In this study, a 210 base pair fragment of the U3-LTR (from
248 to 39) was found to be sufﬁcient for activation of collage-
nase IV gene expression.
Analysis of the necessary FeLV U3-LTR sequence for gene trans-
activation revealed that this region does not have any valid pro-
tein-coding frame. It was demonstrated previously that
leukemogenic viruses such as Mo-MuLV and FeLV generate LTR-
speciﬁc RNA transcripts [11,17]. Other studies on non-oncogenic
endogenous FeLV LTRs demonstrated that they neither make spe-
ciﬁc transcripts like their exogenous counterpart, nor do they
transactivate cellular gene expression [18]. Furthermore, an LTR-
speciﬁc transcript was not detected from total RNA preparation
from feline embryo ﬁbroblast cell line AH927 although it contains
endogenous FeLV LTRs. The functional implication of LTR tran-
script-mediated gene transactivation in virus pathogenesis is not
yet clear, in part because isolated LTRs were used in all earlier
studies. Whether such a transcript is indeed made in FeLV-infected
cells has not been tested. In the present study we investigated pro-
duction of the LTR-speciﬁc transcript in feline cells that actively
produce FeLV. We show that two LTR-speciﬁc small RNAs are gen-
erated in FeLV infected cells. We cloned the smaller transcript of
these RNAs and found that it originates in the U3 region of the
LTR and lies within the minimum sequence necessary for the cellu-
lar gene transactivational activity that we identiﬁed previously.
We also demonstrate that the LTR transcript independently
activates cellular gene transcription.lsevier B.V. All rights reserved.
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2.1. Cell culture and transfection
Feline embryo ﬁbroblast cell line AH927 (a gift from Pradip
Roy-Burman) and HEK293 cells stably expressing mouse-TLR3
(from Invivogen) were maintained in DMEM with 10% fetal calf
serum with 100 U penicillin per ml and 100 lg streptomycin per
ml. Mouse ﬁbroblast line Balb-3T3 was purchased from ATCC and
maintained in the same medium, but with 10% donor calf serum.
AH927 and Balb-3T3 cells were transfected with lipofectamine
plus reagent whereas HEK293-mTLR3 cells were transfected with
lipofectamine 2000 reagent (from Invitrogen), according to the
manufacturer’s protocol. Origin of U3-LTR construct 61E-LTR with
wild-type cellular gene transactivational activity, smaller U3-LTR
constructs clone H (minimal essential region required for cellular
gene transactivation) and Clone G (activity negative) have been de-
scribed earlier [16].
2.2. Virus propagation
AH927 cells were transfected with replication-competent wild-
type FeLV-A molecular clone (61E) or with a transactivational
activity-negative but replication-competent LTR-mutant virus
61E-Mut as above. Transfected cells were passaged at 48 h post-
transfection and then every 3 days until virus production reached
a peak. Virus production was estimated by measuring reverse
transcriptase activity in cell free culture supernatant, as described
previously [16]. Virus antigen level in the culture supernatant was
measured by p27 FeLV core antigen ELISA (Synbiotics Corporation).
2.3. Northern blot
Total cellular RNA from AH927 cells expressing 61E or mutant
virus 61E-Mut at their peak production level was used for Northern
blot analysis. Typically 4–5 passages were necessary for all cells to
become infected and actively produce virus. Total cellular RNA
from these cells was extracted by 4 M guanidine thiocyanate lysis
followed by ultracentrifugation through a 5.7 M CsCl cushion.
Twenty-ﬁve micrograms of each RNA sample were separated in
1% agarose–6.3% formaldehyde gel in 20 mMmorpholine propane-
sulfonic acid (MOPS) buffer and transferred on to Duralon-UV
membrane (Stratagene) by capillary action [19]. Membranes were
hybridized with appropriate 32P-labelled probe using Express-Hyb
hybridization solution (Clontech) according to the manufacturer’s
protocol. DNA templates used for probe preparation were eitherTable 1
Oligonucleotides used in the study.
Namea Sequence (50 to 30)b
30-end RNA ligation linker rAppTTTAACCGCGAATTCCA
50-end RNA ligation linker TGGAATrUrCrUrCrGrGrGr
miRNA-RT GCTGGAATTCGCGGTTAA
miRNA-forward TGGAATTCTCGGGCACCA
F CGGCTTGAGGCCAAGAAC
R TCGAACTCTGGTCAACTG
M6 ACTGGGGAGCtcGGAGACTGC
M7 ATAGCAGAAttCGCGCGTACA
FeLV EnvA GTCAGGACAATAACTGTGAGG
FeLV EnvB CGGTCCCAATCCGTTTGGGAC
T7-F TAATACGACTCACTATAGGCG
a Ligation linkers were purchased from Integrated DNA Technologies.
b Bases with a preﬁx ‘r’ denote ribonucleotides, dd is dideoxynucleotide, lower case l
restriction enzyme sites. T-7 promoter-binding site is underlined in oligonucleotide prim
c Locations of the oligonucleotide primers are based on FeLV-A 61E sequence (Genb
transcript at R.the 341 bp U3-LTR insert in the 61E-LTR plasmid for LTR probe
[11], or a PCR-ampliﬁed product of the envelope region of FeLV
61E using speciﬁc primers (FeLV EnvA and FeLV EnvB, Table 1).
2.4. Small RNA cloning
Total cellular RNA from 61E infected AH927 cells were sepa-
rated on a 1% low melting point agarose gel using RNase-free re-
agents. Approximately 50–250 base size RNAs were puriﬁed and
ligated with preadenylated 30-end ligation linker (Table 1) using
truncated T4 RNA-ligase 2 (New England Biolabs). The 30-end
ligated RNA was then further ligated with 50-end ligation linker
(Table 1) using T4 RNA ligase 1 followed by phenol–chloroform
extraction and ethanol precipitation. The RNA linkers were pur-
chased from Integrated DNA Technologies. The doubly end-ligated
RNA was then reverse transcribed using miRNA-RT primer and PCR
ampliﬁed with miRNA-F primer (Table 1). PCR products of approx-
imately 50–300 bp sizes were puriﬁed from agarose gel and cloned
in pGEMT-easy T-A cloning system (Promega). Recombinant colo-
nies were directly screened for LTR speciﬁc sequences by colony
hybridization using the same 32P-labeled LTR probe used for
Northern blot described earlier. Inserts of the recombinant clones
were analyzed by automated DNA sequencing.
2.5. In vitro transcription of LTR transcript and RNA transfection
To synthesize the 104 base LTR-RNA transcript that we cloned,
we PCR ampliﬁed this sequence with forward (T7-F) and reverse
primer (R) described in Table 1 using 61E-LTR as template. The pri-
mer T7-F in this PCR reaction had additional T7 promoter-binding
sequence. The ampliﬁed PCR product with a T7 promoter-binding
site was then used as template for RNA synthesis in vitro in stan-
dard T7-RNA polymerase reaction followed by DNase digestion,
ethanol precipitation and spectrophotometric quantitation. To syn-
thesize ﬂuorescein-labeled LTR transcript, similar in vitro synthesis
protocol was used using ﬂuorescein RNA labeling mixture (Roche
Applied Bioscience). Quality and size of the product was veriﬁed
in 4% polyacrylamide gel using RNA molecular weight standards
from Invitrogen. For RNA transfection in HEK293-mTLR3 cells,
LTR transcript RNA or yeast t-RNA and NFjB-dependent luciferase
reporter plasmid (3KB-Luc) were mixed together before complex
formation was initiated with lipofectamine 2000 reagent. Cells
were harvested from luciferase activity 24 h post-transfection.
Transfection of ﬂuorescein-labeled RNA transcript to HEK293-
mTLR3 cells was also done by lipofectamine 2000 reagent. Cells
were ﬁxed with 4% paraformaldehyde solution in PBS and mountedLocationc
G/ddC
CrArCrCrArArGrGrU
61E U3LTR 197 to 180
61E U3LTR 94 to 111
61E U3LTR 108 to 128
61E U3LTR 28 to 48
61E gp70 6167 to 6187
61E gp70 6499 to 6479
GCTTGAGGCCAAGAAC T7 promoter at the 50 of ‘F’
etters in M6 and M7 denote deviation from original sequence introduced to create
er T7-F.
ank accession number M18247) where +1 is the beginning of the genomic RNA
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taining 40,6-diamidino-2-phenylindole (DAPI).
3. Results
3.1. LTR-speciﬁc small RNAs are made in FeLV-infected feline AH927
cells
Our previous work with isolated FeLV LTRs suggested that U3-
LTR-speciﬁc transcripts are generated from the LTR. To determine
whether such transcripts are made naturally in virus-infected cells,
we analyzed total cellular RNA from feline embryo ﬁbroblast
AH927 cells that were actively-producing FeLV-A virus 61E. To
strengthen our analysis, we also included RNA from AH927 cells
infected with a LTR mutant virus (61Mut), which replicates with
similar kinetics as of 61E but does not support cellular gene trans-
activation as reported earlier [16], and also RNA from uninfected
AH927 cells. We measured p27 core antigen level and reverse
transcriptase activity in the culture supernatants for both viruses
and conﬁrmed that they both had comparable level of virus pro-
duction (Fig. 1A and B). Northern blot analysis with a LTR-speciﬁc
probe detected one band of less than 200 base in both 61E and 61E-
Mut RNA preparations, albeit in lesser amount in the mutant virus
(Fig. 2C). Although full-length genomic RNA (8.0 kb) and singly-1,004 95Mock
38,629 20761E-Mut
47,394 12561E
RT activity/cpm/25µlVirus
0.026 0.007-ve Control
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Fig. 1. Detection of LTR-speciﬁc small RNAs in FeLV infected AH927 cells. AH927 cells tra
mutant 61E-Mut were passaged ﬁve times before analysis to allow spread of virus infec
activity (A) and p27 antigen ELISA (B). Positive and negative controls for the ELISA were s
assays. Northern blotting was performed with either FeLV LTR-speciﬁc or Env-speciﬁc 3
from the relative location of 28S and 18S ribosomal RNAs on a photograph fo the ethidiu
demonstrate equal loading and quality of RNA preparations.
Fig. 2. Mapping of the LTR transcript. Coordinates of the LTR transcript are shown on the F
positive U3-LTR clones used in our earlier studies. Location and orientation of the smallspliced env RNA (3.0 kb) were readily detected, visualization of
LTR-speciﬁc small RNA transcripts required probing as much as
25 lg of total cellular RNA per lane. To verify further the LTR origin
of this band we used a different probe corresponding to only FeLV
envelope gp70 region in separate Northern hybridization experi-
ment. Both the genomic RNA and spliced env RNA were detected
with this probe, as with LTR probe, but not the small RNA tran-
script (Fig. 2C). As expected, the RNA from uninfected AH927 cells
did not react to either probe. In some experiments we also found
another transcript (approximately 350 bases) that hybridized with
LTR probe only. The discrete and reproducible appearance and size
of the small LTR-speciﬁc transcripts suggested that the small RNA
species detected were not degradation product of the larger RNA
species. These data thus demonstrated that LTR-speciﬁc small
RNAs are made during FeLV infection.
3.2. Coordinates of the FeLV LTR transcript lie within the U3 region
To begin characterization of the small LTR transcript generated
from FeLV, we molecularly cloned the RNA using an approach typ-
ically used for cloning small non-coding RNAs. As we had previ-
ously demonstrated that a 210 bp U3-LTR region (clone H) was
sufﬁcient for gene transactivation and produced RNA transcripts
[16], we focused our attention on characterizing the smaller of61
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nsfected with replication competent full-length FeLV molecular clone 61E or the LTR
tion. Virus titer in the culture supernatant was measured by reverse transcriptase
upplied in the kit. Standard deviation was calculated with data from three separate
2P-labelled probes (C). Molecular weight of the primary transcripts was estimated
m bromide-stained gel (D). The ethidium bromide-staining pattern was also used to
eLV 61E LTR sequence. Clone 61E-LTR and clone H are the transactivational activity-
LTR-transcript is shown. ‘R’ is the beginning of normal genomic transcript.
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the smaller RNA transcript from low melting agarose gel and li-
gated at both the 50- and 30-ends using a speciﬁc RNA cloning lin-
ker. Ligated product was then reversed transcribed and subjected
to PCR ampliﬁcation using primers that were homologous to the
RNA cloning linker. PCR products up to 300 bp were gel-puriﬁed
and cloned into pGEMT-Easy T-A cloning vector and screened by
colony hybridization. We identiﬁed one colony that strongly
hybridized with the LTR probe, puriﬁed the clone, and the plasmid
was sequenced in its entirety. The cloned transcript was identiﬁed
as a 104 base positive-sense RNA fragment, which exactly matched
the FeLV 61E proviral sequence from 197 to 93 (+1 being the
start of R). The orientation of the cloned RNA was determined from
the 50-end and 30-end RNA linker sequences in the clone. This se-
quence does not have any open protein-coding frame. The se-
quence coordinates of this LTR-RNA transcript as well as the two
other U3-LTR clones, 61E-LTR and clone H, are shown in Fig. 2.
The relative position of this transcript in comparison to the other
LTR clones used in our study is shown in Fig. 3A. Interestingly,
the coordinates of the LTR-RNA transcript lie fully within the min-
imum sequence necessary for gene transactivation activity (Clone
H) that we identiﬁed previously [16].
3.3. Small LTR transcript transactivates gene expression
We next wished to determine whether the LTR-RNA transcript
is biologically active. To address this question we subcloned the
104 bp DNA sequence that encodes the LTR transcript, into the
pGEMT vector and tested its transactivation potential in a NFjB-0
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Fig. 3. Transactivational activity of the U3-LTR transcript RNA. (A) Location of the LTR tr
primers used to amplify speciﬁc regions of the LTR are indicated by open and closed box
plasmid clones. Balb-3T3 cells were co-transfected with various LTR plasmid clones and N
harvested for luciferase assay 48 h after transfection. (C) Transactivational activity of
synthesized LTR transcript RNA or yeast tRNA (200 or 400 ng) and reporter plasmid 3
control in all RNA transfections. Error bars were calculated from three independent trandependent luciferase reporter assay. We also tested the in vitro
synthesized LTR transcript RNA in similar NFjB reporter assays.
We found that the plasmid clone of the LTR transcript (F-R) was
unable to transactivate the NFjB-dependent reporter (Fig. 3B) in
Balb-3T3 cells. The 61E-LTR and clone H, but not clone G, induced
reporter expression as we have reported previously [16]. To verify
that in vitro synthesized RNA can be introduced into the cells, we
transfected ﬂuorescein-labeled LTR RNA in HEK293-mTLR3 cells
and analyzed the presence of the LTR transcript in cells by immu-
noﬂuorescence microscopy. We chose HEK293-mTLR3 cells over
Balb-3T3 cells for this purpose because of their higher transfection
efﬁciency and suitability for RNA transfection. We also have shown
previously that these cells support LTR-mediated NFjB transacti-
vation. As shown in Fig. 4, transfected LTR transcript was readily
detected inside the cells. In reporter assays, the LTR-RNA transcript
strongly activated expression of NFjB-dependent luciferase gene
in a dose-dependent manner (Fig. 3C). Transfected yeast tRNA
(small RNAs of comparable size to the LTR transcript) however,
failed to activate the NFjB reporter in the same assay. Our data
thus demonstrated that the LTR transcript we identiﬁed and cloned
in this study is biologically active. The failure of the DNA equiva-
lent of the LTR transcript to transactivate gene expression on the
other hand, suggested the need for additional sequences for its
activity.
4. Discussion
Several earlier studies suggested that the cancer-related cellular
gene transactivational activity of the U3-LTR region of leukemia0
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anscript clone F-R and other U3-LTR constructs used in this study. Locations of the
es (forward and reverse primers, respectively). (B) Transactivational activity of the
FjB-dependent reporter plasmid 3xKB-Luc as described previously [14]. Cells were
the LTR transcript RNA. HEK293-mTLR3 cells were co-transfected with in vitro
KB-Luc. Two hundred nanograms of pTZ19U plasmid vector DNA was included as
sfections.
Fig. 4. Internalization of in vitro synthesized RNA by transfection. Fluorescein-
labeled in vitro synthesized LTR transcript RNA was transfected in HEK293-mTLR3
cells by lipofectamine 2000 reagent and visualized 16 h post-transfection by
ﬂuorescence microscopy. (A) Fluorescence, (B) bright ﬁeld, (C) DAPI, and (D) merge
of A and C.
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viruses. Our previous studies showed that the gene transactiva-
tional activity of FeLV LTR is related to its ability to make a small
non-coding RNA transcript [18]. It was not known however
whether such a non-coding RNA is made during actual virus infec-
tion, and if it is, whether that RNA would have any role in cellular
gene transactivation. In this study we demonstrated that small
LTR-speciﬁc RNA transcripts are made from FeLV infected cells.
Cloning and sequence analysis of the transcript conﬁrmed that
the coding region of this transcript is within the U3 region of the
LTR. We also demonstrated that the LTR transcript RNA we identi-
ﬁed in this study independently activates NFjB signaling. There-
fore, our data suggest that production of LTR-speciﬁc small RNA
plays a role in cellular gene transactivation.
Oncogene-deﬁcient retroviruses such as Moloney MuLV and
FeLV induce tumor development in all infected animals with a pre-
dictable time course. Although insertional activation of proto-
oncogene is the most well understood mechanism of tumorigene-
sis, the non-speciﬁc nature of retrovirus integration suggests
important role of other virus-directed mechanisms in pathogene-
sis. Our data demonstrate that LTR-speciﬁc small non-coding RNAs
are generated in FeLV-infected cells, which then activates the NFjB
signaling pathway. As chronic stimulation of NFjB signaling has
been linked to the development of various cancers [20], our ﬁnd-
ings provide an alternate mechanism that may contribute in leuke-
mia virus pathogenesis. Further characterization of the promoter
elements for this LTR transcript will be necessary to understand
the control of its expression. Our data suggests that these elements
very likely exist outside the coding region of this transcript. Anal-
ysis of expression of this transcript in infected animals and its role
in tumor development would be interesting future direction of this
work.Acknowledgements
We appreciate the technical assistance of Virginia Newman.
This work was supported in part from a New Investigator Grant
from Massachusetts division of American Cancer Society (S.K.G.),
Institutional Research Grant IRG7200124 from the American Can-
cer Society (S.K.G.), a Grant from Aids for Cancer Research
(S.K.G.), a Grant from the National Cancer Institute (CA112102)
and the Karin Grunebaum Cancer Research Foundation (D.V.F.).
References
[1] Fan, H. (1997) Leukemogenesis by Moloney murine leukemia virus: a multi-
step process. Trends Microbiol. 5, 74–82.
[2] Selten, G., Cuypers, H.T. and Berns, A. (1985) Proviral activation of the putative
oncogene pim-1 in MuLV-induced T cell lymphomas. EMBO J. 4, 1793–1798.
[3] Levy, L.S., Lobelle-Rich, P.A. and Overbaugh, J. (1993) Flvi-2, a target of
retroviral insertional mutagenesis in feline thymic lymphosarcomas, encodes
bmi-1. Oncogene 8, 1833–1838.
[4] Tsatsanis, C., Fulton, R., Nishigaki, K., Tsujimoto, H., Levy, L., Terry, A.,
Spandidos, D., Onions, D. and Neil, J.C. (1994) Genetic determinants of feline
leukemia virus-induced lymphoid tumors: patterns of proviral insertion and
gene rearrangement. J. Virol. 68, 8296–8303.
[5] Short, M.K., Okenquist, S.A. and Lenz, J. (1987) Correlation of leukemogenic
potential of murine retroviruses with transcriptional tissue preference of the
viral long terminal repeats. J. Virol. 61, 1067–1072.
[6] Golemis, E., Li, Y., Fredrickson, T.N., Hartley, J.W. and Hopkins, N. (1989)
Distinct segments within the enhancer region collaborate to specify the type
of leukemia induced by nondefective Friend and Moloney viruses. J. Virol. 63,
328–337.
[7] Chatis, P.A., Holland, C.A., Silver, J.E., Frederickson, T.N., Hopkins, N. and
Hartley, J.W. (1984) A 30 end fragment encompassing the transcriptional
enhancers of nondefective Friend virus confers erythroleukemogenicity on
Moloney Leukemia virus. J. Virol. 52, 248–254.
[8] Davis, B., Linney, E. and Fan, H. (1985) Suppression of leukaemia virus
pathogenicity by polyoma virus enhancers. Nature 314, 550–553.
[9] Davis, B.R., Brightman, B.K., Chandy, K.G. and Fan, H. (1987) Characterization of
a preleukemic state induced by Moloney murine leukemia virus: evidence for
two infection events during leukemogenesis. Proc. Natl. Acad. Sci. USA 84,
4875–4879.
[10] Faller, D.V., Weng, H. and Choi, S.Y. (1997) Activation of collagenase IV gene
expression and enzymatic activity by the Moloney murine leukemia virus long
terminal repeat. Virology 227, 331–342.
[11] Ghosh, S.K. and Faller, D.V. (1999) Feline leukemia virus long terminal repeat
activates collagenase IV expression through AP-1. J. Virol. 73, 4931–4940.
[12] Weng, H., Choi, S.Y. and Faller, D.V. (1995) The Moloney leukemia retroviral
long terminal repeat trans-activates AP-1-inducible genes and AP-1
transcription factor binding. J. Biol. Chem. 270, 13637–13644.
[13] Faller, D.V., Weng, H., Graves, D.T. and Choi, S.Y. (1997) Moloney murine
leukemia virus long terminal repeat activates monocyte chemotactic protein-
1 protein expression and chemotactic activity. J. Cell. Physiol. 172, 240–252.
[14] Abujamra, A.L., Spanjaard, R.A., Akinsheye, I., Zhao, X., Faller, D.V. and Ghosh,
S.K. (2006) Leukemia virus long terminal repeat activates NFkappaB pathway
by a TLR3-dependent mechanism. Virology 345, 390–403.
[15] Choi, S.Y. and Faller, D.V. (1994) The long terminal repeats of a murine
retrovirus encode a trans-activator for cellular genes. J. Biol. Chem. 269,
19691–19694.
[16] Abujamra, A.L., Faller, D.V. and Ghosh, S.K. (2003) Mutations that abrogate
transactivational activity of the feline leukemia virus long terminal repeat do
not affect virus replication. Virology 309, 294–305.
[17] Choi, S.Y. and Faller, D.V. (1995) A transcript from the long terminal repeats of
a murine retrovirus associated with trans activation of cellular genes. J. Virol.
69, 7054–7060.
[18] Ghosh, S.K., Roy-Burman, P. and Faller, D.V. (2000) Long terminal repeat
regions from exogenous but not endogenous feline leukemia viruses
transactivate cellular gene expression. J. Virol. 74, 9742–9748.
[19] Pal-Ghosh, R. andMorrow, C.D. (1993) A poliovirus minireplicon containing an
inactive 2A proteinase is expressed in vaccinia virus-infected cells. J. Virol. 67,
4621–4629.
[20] Okamoto, T., Sanda, T. and Asamitsu, K. (2007) NF-kappa B signaling and
carcinogenesis. Curr. Pharm. Des. 13, 447–462.
